Le Lézard
Classified in: Health
Subject: v

Sienna Announces December Dividend


MARKHAM, Ontario, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of December 2019, representing $0.936 per Common Share on an annualized basis.

The dividend will be payable on January 15, 2020 to shareholders of record as at December 31, 2019. 

The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

Sienna has a Dividend Reinvestment Plan (the "DRIP") which allows eligible shareholders of the Company to direct that their cash dividends be reinvested in additional Common Shares. Common Shares issued pursuant to the DRIP are issued from treasury at a 3% discount from the market price. Participation in the DRIP is optional and shareholders who do not wish to participate in the DRIP will continue to receive cash dividends. A complete copy of the DRIP is available under the Investors section of the Company's website.

ABOUT SIENNA SENIOR LIVING

Sienna Senior Living Inc. (TSX:SIA) is a leading seniors' living provider with 84 seniors' living residences in key markets in Canada. Sienna offers a full range of seniors' living options, including independent living, assisted living, long-term care, and specialized programs and services. Sienna also provides expert management services. Sienna is committed to national growth, while driving long-term value for shareholders. The Company's approximately 12,000 employees are passionate about helping residents live fully every day, and were the driving force behind Sienna being named one of Canada's Most Admired Corporate Cultures in 2017. For more information, please visit www.siennaliving.ca

CONTACT:

Nitin Jain
Chief Financial Officer & Chief Investment Officer
(905) 489-0787
[email protected]


These press releases may also interest you

at 22:18
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...



News published on and distributed by: